A New Era of Genome Damage Response at the Forefront of Brain Disorders Therapy by Muralidhar L. Hegde, PhD, F-ABAP

Houston Methodist is committed to excellence in research, teaching, patient care and the advancement of the art and science of medicine. Houston Methodist is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This website uses cookies to improve website functionality and performance, to analyze website traffic, and to provide you with a more personalized experience. To find out more about the cookies we use, see our Digital Privacy Policy, Disclaimer & Terms of Use.

A New Era of Genome Damage Response at the Forefront of Brain Disorders Therapy by Muralidhar L. Hegde, PhD, F-ABAP

From ioifelayo@houstonmethodist.org

views

Muralidhar L. Hegde, PhD, F-ABAP

Associate Professor, Department of Neurosurgery

Center for Neuroregeneration

Houston Methodist

Genome damage and defective repair are etiologically linked to neurodegeneration and brain hemorrhage. However, the specific mechanisms involved and their implications remain enigmatic, a roadblock for developing effective mechanism-based therapies. Our recent studies (Wang et al, Nature Communications, 2018; Mitra et al, PNAS, 2019; Guerrero et al, Hum Mol Gent, 2020; Dharmalingam et al, ACS Nano, 2020) uncovered novel mechanisms of DNA repair defects in motor neuron disease amyotrophic lateral sclerosis (ALS) and brain hemorrhage (ICH) patients, paving the way for DNA repair-targeted therapies to prevent or slow down disease progression. This research is supported by National Institutes of Health and Houston Methodist.

Recorded in the Houston Methodist Research Institute Ernest H. Cockrell Boardroom R2-311 on Wednesday, September 2, 2020.

Tags

A New Era of Genome Damage Response at the Forefront of Brain Disorders Therapy by Muralidhar L. Hegde, PhD, F-ABAP

Related Media